PLAN-LES-OUATES GENEVA, SWITZERLAND -- 07/03/09 --
Geneva, Switzerland, 2 July 2009 - Allosteric modulation company
Addex Pharmaceuticals (SIX: ADXN) invites investors, analysts, media
and other interested parties to attend its annual R&D day on
Thursday, July 16, 2009 in Geneva, Switzerland.
Addex management will discuss advances made with its small molecule
allosteric modulator drug discovery platform as well as the status of
multiple drug candidates, including the clinical-stage products
ADX10059, ADX48621 and ADX71149, which are in development for
gastroesophageal reflux disease (GERD), migraine prevention,
Parkinson's disease, schizophrenia and anxiety. Addex also will
disclose new early stage programs for important indications in
metabolic disease and inflammation.
What: Addex Pharmaceuticals R&D Day
When: 11:00am CCET to 3:30pm CET, July 16, 2009
Where: 14, Chemin des Aulx
1228 Plan-les-Ouates, Geneva
Switzerland
Interested parties are encouraged to attend in person. A complete
program will be made available on our website prior to the event.
Please email investor.relations@addexpharma.com or
media.relations@addexpharma.com for more information.
The Addex R&D Day presentations, related question and answer sessions
and supporting documents will be webcast live and made available
thereafter via www.addexpharma.com.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops
allosteric modulators for human health. Allosteric modulators are a
different kind of orally available small molecule therapeutic agent,
which we believe will offer a competitive advantage over classical
drugs. Our lead allosteric modulator product, ADX10059, has achieved
clinical proof of concept and is in Phase IIb testing for the
treatment of GERD and, separately, migraine headache. Both are
important diseases for which existing products with limited efficacy
have established multi-billion dollar markets despite sub-optimal
efficacy. ADX10059 is a first-in-class mGluR5 inhibitor, a
therapeutic strategy that also is being pursued in multiple
indications by large pharma competitors.
Our products and technology already have proven their value through
our partnerships with four of the top 10 pharmaceutical companies in
the world. Specifically, an agreement with Ortho-McNeil-Janssen Inc.
is focused on development of allosteric modulators to treat anxiety
and schizophrenia. In addition, in two separate agreements with Merck
& Co., Inc., we are developing allosteric modulators as drugs to
treat Parkinson's disease and schizophrenia, respectively. Finally,
GlaxoSmithKline and Roche have made equity investments in Addex.
Chris Maggos
Head of IR & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com
Disclaimer
The foregoing release may contain forward-looking statements that can
be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would",
"could", or similar expressions, or by express or implied discussions
regarding Addex Pharmaceuticals Ltd, its business, the potential
approval of its products by regulatory authorities, or regarding
potential future revenues from such products. Such forward-looking
statements reflect the current views of Addex Pharmaceuticals Ltd
regarding future events, future economic performance or prospects,
and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other
factor that may materially differ from the plans, objectives,
expectations, estimates and intentions expressed or implied in such
forward-looking statements. Such may in particular cause actual
results with allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by
such statements. There can be no guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 will be approved for sale in any
market or by any regulatory authority. Nor can there be any guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 or other
therapeutic targets will achieve any particular levels of revenue (if
any) in the future. In particular, management's expectations
regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 or
other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or
delays or government regulation generally; unexpected clinical trial
results, including unexpected new clinical data and unexpected
additional analysis of existing clinical data; competition in
general; government, industry and general public pricing pressures;
the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of
these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from
those anticipated, believed, estimated or expected. Addex
Pharmaceuticals Ltd is providing the information in this press
release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release
as a result of new information, future events or otherwise, except as
may be required by applicable laws.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
